Endpoints Webinars

Life sciences marketers work with long sales cycles and products that require market education — which make webinars one of the most essential tools in the biopharma demand generation toolbox. 

Endpoints webinars are a turn-key solution — let us handle the audience generation, content, marketing, and tech.

Upcoming Webinars

State of the union for advanced medicines

Using external data to accelerate randomized controlled trials without introducing bias

Different approaches to process development and manufacturing in gene therapy

Checkpoint inhibitors: the gut microbiome’s role in anti-tumor response

Enterprise R&D transformation case study: Genentech

CQV strategies that increase speed-to-market for gene therapy

Navigating your biopharma drug candidate through early and mid-stage clinical trials

past Webinars

CQV strategies to optimize cell therapy manufacturing

Innovations in clinical trial design with ctDNA MRD

Developing the next big vaccine technologies

Running decentralized trials at scale

mHealth innovation: identifying the best patient-centered technology for your trial needs

How biotechs have found success with University of Florida technologies

Changing the game: an examination of cutting-edge novel oncology screening tools

Scaling up a gene therapy manufacturing facility

A new class of startups is scouting for deals - on both sides of the Pacific

DEL like never before - 4th generation of DEL kits

Driving efficiencies through virtual trial solutions in Asia Pacific

After a decade of consolidation, who rules the CRO roost?

Concept to dosing: Challenges in new orphan drugs

Is the AI revolution empowering the scientist?

How Regeneron scaled its cloud to support millions of samples a year

Can changing one step change everything? Replacing your polishing step with a single-use solution

Pricing strategies for advanced therapies

HQ plasmid DNA: a case for phase dependent approaches to manufacturing

Non-clinical and clinical pathways for rapid vaccine development in Australia

Leading with data: tumor-informed ctDNA testing across cancer types

After the pandemic, antibody R&D remains key

Strategies for building a cell therapy manufacturing facility

The neurosciences comeback: After a lengthy chill, Big Pharma is warming back up to neuro

Recent key advances in autologous stem cell-derived therapies

Expedited clinical development strategies for China

Protein degradation: Looking back and moving forward

Enrolling a global study ahead of schedule (during a pandemic)

The big platform plays have been in vogue. But for how long?

Essential strategies for gene therapy - from assay development to CDx commercialization

Innovation in drug product manufacturing: how do we bring new therapies to patients faster?

KRAS G12C Is Now Actionable in NSCLC!

Life science SPACs – the future of IPOs/crossover investing? A look at 2021/2022

Kantar Health on the most impactful trials at ASCO

Reinventing Harvest Technology: Single-stage chromatography clarification for recombinant protein therapeutic manufacturing

Reengineering CAR-T for solid tumors

Informed by the tumor: new data on the power of a personalized ctDNA assay

Deconvoluting inflammation and immunology for clinical trials

How scalable and intensified is your CAR-T process?

Improving endpoint selection in Alzheimer’s disease trials

Are we ready for the medicines of tomorrow? Creating the infrastructure for the era of genomic medicine

Plasmid DNA Insights: Expanded focus on CMC in gene & cell therapy development

Developing and using digital biomarkers

Transformative approaches to clinical development: Scaling adoption across the industry

Realizing the full potential of clinicogenomics

Hot topics in Immunoassay Bioanalysis - navigating the immunogenicity and biomarker requirements for clinical trials

The Great Debate: Internal vs. external manufacturing for advanced therapies

Predict placebo response using patient psychology to increase trial power

Can sponsors collect data in Expanded Access (EAPs) and Named Patient Programs (NPPs)?

Clinical trial diversity in the Covid-19 era — are we seeing a paradigm shift?

The benefits of running clinical trials in China

Where does your organization sit on the omnichannel maturity curve?

Flattening the 'valley of death:' New tools in the hunt for better preclinical R&D

Repurposing drugs for new indications: benefits and challenges

Leveraging APAC partnerships to de-risk clinical trials

Patient-First R&D: Why the patient experience should be at the center of clinical trial design

Navigating the path to the clinic and beyond for gene therapies

Beyond AAV 1.0

Enabling multidimensional tumor immunogenomics for advancing biomarker discovery

Breakthrough Technologies to Accelerate Biologic Drug Discovery, Cell Line Development and Biomanufacturability

How the World’s First Biolabs Client Portal GALEXI™ Delivers Real-Time Study Management for Biotechs

The Patient Voice in Rare Disease Research

Redefining conditioning for a new era of gene therapy

DEL Kits Special Event: A New Method of Hit Discovery

Optimizing Direct-to-Patient Clinical Supply for Decentralized Clinical Trials

Amgen’s BiTE® Platform and the Next Frontier in Immuno-Oncology

Innovation in Clinical Research: AI-based Drug Development Tools and the Regulatory Landscape

R&D in an age of Covid-19: Tackling the key issues around starting, or restarting an early-stage study

Solving hard go-to-market challenges

New Platform for Target-to-Hit: From Fragment Screen to Structure-based Drug Discovery

Introduction to Self-Service DNA-Encoded libraries (DELs)

Keeping Pace with Big Pharma - On A Start Up Budget

Putting AI in R&D

Managing Global Studies with Regional Partners

Faster, More Efficient Trials: Novel Trial Designs using Digital Twins

Why Australia is the World’s Leading Early Phase Destination – Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs

The Transformation of Clinical Trial Design and Operations: A Panel Discussion on COVID-19 as a Catalyst for Decentralized Trials

AI, Digital Twins, and the Future of Clinical Research

When cell and gene therapies surge to market, how resilient will your cell sourcing infrastructure be?

The Australian Early Phase Biosimilars Clinical Trial Landscape - How Agilex Biolabs and Nucleus Network Work Together

The FDA and Covid-19: New rules for the R&D road

Novel oncology trial designs with a personalized ctDNA assay

Derisking orphan drug programs in 2020 and beyond

A Clinical Investigator’s Perspective: Novel Oncology Therapy During & Beyond the COVID Pandemic

Home Nursing Support for Clinical Trials

Running First-in-human and Vaccines Studies in Australia

How Easy is it to Move your Clinical Trials to Australia?

Utilizing the immunoSEQ Assay in Clinical Trials

The Covid-19 challenge: Keeping the supply chain intact

Endpoints Editor John Carroll's Covid - 19 webinar series

Dealmaking in a time of coronavirus

Advancing Oncology Clinical Trials in Asia-Pacific

Asia-Pacific – a Global hub for Hepatology Clinical Trials

Perspectives on Partnering Post-Pandemic

Clinical Trial Continuity in Asia-Pacific during the COVID-19 Pandemic

The Australian Advantage: De-risk your early phase trials

Rapid Deployment of Remote Trials During Containment

RWD for R&D: Examples from Immunology, Rheumatology and Other Chronic Diseases

Designing a turnkey orphan drug program

The do’s and don’ts of managing a pivotal gene therapy trial

You've got that coveted accelerated regulatory pathway. Now what?

Developing better assays for biopharma with a CRO partner

Are you really ready for your end of phase 2 meeting?

How to run a Digital Trial and reduce time in development by 50%

Improving Clinical Trial Quality with Best Practices for E-Clinical Technology

Developing a digital therapeutics trial

The Experts: Real World Endpoints

Designing Next-Gen Oncology Trials

ctDNA as a biomarker for monitoring treatment response and molecular recurrence in early-stage and metastatic cancers

How to get the most out of your Phase I biologic study

The Alzheimer's Trials of the Future